Horizon lays out $65M for in-house manufacturing plant as eye med Tepezza resets course to blockbusterland

As Horizon Therapeutics' one-and-a-half-year-old thyroid eye disease med Tepezza starts to spread its wings, the drugmaker is standing up in-house manufacturing to help blunt any further supply disruptions.